Biblio

Author Title [ Type

] Year

Filters: Author is Park, Jae H [Clear All Filters]

Journal Article

Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4(16):3977-3989.

Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg MLynne, Batlevi Y, Shouval R, Devlin SM, Batlevi C, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.

Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.

Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MRosa, Fraser K, Subklewe M, et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023.

Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao JJ, Casanova J, Lin Y-TDavid, Petrova-Drus K, Mohanty AS, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.

Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023;11(8).

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021.

Wudhikarn K, King AC, Geyer MBlaine, Roshal M, Bernal Y, Gyurkocza B, Perales M-A, Park JH. Outcomes of Relapsed B-Cell Acute Lymphoblastic Leukemia After Sequential Treatment with Blinatumomab and Inotuzumab. Blood Adv. 2022.

Diamond BT, Ziccheddu B, Maclachlan KH, Taylor J, Boyle EMary, Ossa JEsteban Ar, Jahn TJacob, Affer M, Totiger TM, Coffey DG, et al. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023.